All In Biotech

Drug Trial Radar · NCT06300411

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery

A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Jul 29, 2024

Primary completion

Apr 8, 2026

Study completion Apr 8, 2026

Sponsor

Lead sponsor
SURGE TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.

Conditions

  • Breast Cancer

Interventions

  • SRG-514Drug

    SRG-514 monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]Time frame: 14 days
  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Time on trial up to 60 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Health

    Savannah, Georgia

  • Indiana University

    Indianapolis, Indiana

  • Mayo

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • NYU Langone Health

    New York, New York

  • Duke Cancer Center

    Durham, North Carolina

  • MD Anderson Cancer Center

    Houston, Texas

  • Audie Murphy VA

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.